Familial Waldenstrom's macroglobulinemia
- PMID: 12720125
- DOI: 10.1053/sonc.2003.50063
Familial Waldenstrom's macroglobulinemia
Abstract
The etiology of Waldenstrom's macroglobulinemia (WM) is unknown. A possible role for genetic factors has been suggested by reports of familial clustering of WM. However, it is not yet possible to define the proportion of all WM that occurs in the familial setting. Review of the data on the 12 families published since 1962 suggests that familial WM may differ from sporadic disease in certain respects. Among these families, there is a pronounced occurrence of a variety of immunologic abnormalities in the relatives of WM cases. Notably, the prevalence of IgM monoclonal gammopathy (IgM MG) in first-degree relatives of WM cases was reported to be as high as 6.3%, representing a 10-fold increase relative to general population estimates. IgM MG has been shown to progress to WM at a rate of approximately 1.5% per year in a large case series; whether this rate of progression is altered in familial WM is unknown. Although limited by small numbers and a lack of systematic ascertainment and evaluation, these data are intriguing and provide a compelling basis for further study and systematic investigation of WM in families.
Similar articles
-
Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):19-22. doi: 10.3816/CLM.2009.n.003. Clin Lymphoma Myeloma. 2009. PMID: 19362963 Free PMC article.
-
A case-control and family study of Waldenstrom's macroglobulinemia.Leukemia. 1993 Sep;7(9):1363-9. Leukemia. 1993. PMID: 8371587
-
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.Semin Oncol. 2003 Apr;30(2):110-5. doi: 10.1053/sonc.2003.50082. Semin Oncol. 2003. PMID: 12720118 Review.
-
Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden.Acta Oncol. 2016;55(1):91-8. doi: 10.3109/0284186X.2015.1096019. Epub 2015 Nov 11. Acta Oncol. 2016. PMID: 26559865
-
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.Best Pract Res Clin Haematol. 2016 Jun;29(2):187-193. doi: 10.1016/j.beha.2016.08.015. Epub 2016 Sep 4. Best Pract Res Clin Haematol. 2016. PMID: 27825465 Review.
Cited by
-
Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.J Natl Cancer Inst Monogr. 2014 Aug;2014(48):87-97. doi: 10.1093/jncimonographs/lgu002. J Natl Cancer Inst Monogr. 2014. PMID: 25174029 Free PMC article.
-
Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):19-22. doi: 10.3816/CLM.2009.n.003. Clin Lymphoma Myeloma. 2009. PMID: 19362963 Free PMC article.
-
Current and novel BTK inhibitors in Waldenström's macroglobulinemia.Ther Adv Hematol. 2021 Feb 7;12:2040620721989586. doi: 10.1177/2040620721989586. eCollection 2021. Ther Adv Hematol. 2021. PMID: 33613931 Free PMC article.
-
Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?Ther Adv Hematol. 2024 Dec 23;15:20406207241308771. doi: 10.1177/20406207241308771. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39734591 Free PMC article. Review.
-
Novel agents in Waldenström macroglobulinemia.Clin Investig (Lond). 2011;1(6):815-824. doi: 10.4155/CLI.11.60. Clin Investig (Lond). 2011. PMID: 22034589 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources